Atea Pharmaceuticals announced the results of its 2026 Annual Meeting of Stockholders held on June 18, 2026. All proposals presented were approved by the company's shareholders, including the election of three Class III directors.
Key Details
- Director Election: Dr. Jerome Adams, Dr. Howard Berman, and Barbara Duncan were elected as Class III directors to serve until the 2029 annual meeting.
- Auditor Ratification: Shareholders ratified the appointment of KPMG LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Executive Compensation: A non-binding advisory proposal to approve the compensation of the company's named executive officers was also approved.